Alvotech vs BioCryst Pharmaceuticals
ALVO and BCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALVO and BCRX compare
BioCryst Pharmaceuticals grew revenue faster over the last twelve months (68.7% versus 19.7% for Alvotech).
BioCryst Pharmaceuticals scores higher on the StockData Score (9 against 3 for Alvotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALVO | BCRX |
|---|---|---|
| Size and price | ||
| Market cap | – | $1.9B |
| Share price | $4.37 | $7.50 |
| Change, 1 year | −20.4% | 5.9% |
| Change, 5 years | −55.8% | −39.9% |
| Beta (5Y) | 0.37 | 0.58 |
| Employees | 1,000 | 435 |
| StockData Score | ||
| Total score | 3 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 4 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 2.0× |
| P/FCF | – | 5.1× |
| FCF yield | – | 19.5% |
| Growth | ||
| Revenue growth (TTM) | 19.7% | 68.7% (better) |
| Revenue growth, 5Y average | 54.5% | 118% (better) |
| Profitability | ||
| Gross margin | 59.8% | 97.8% (better) |
| Operating margin | 13.3% (better) | −33.3% |
| Net margin | – | −40.9% |
| FCF margin | −19.6% | 39.7% (better) |
| Financial health | ||
| Net debt / EBITDA | 10.02 | – |
| Interest coverage | 0.5× (better) | −4.2× |
| Current ratio | 1.65 | 2.32 (better) |
| Altman Z-score | – | −3.83 |
| Piotroski F-score | – | 7 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 103% |
| Held by insiders | 67.7% | 1.9% |
| Insider net buying, 12 months | – | −$4.1M |
| Short interest, % of float | – | 11.0% |
Go deeper
- ALVO stock overview
- ALVO income statement
- ALVO valuation and score
- BCRX stock overview
- BCRX income statement
- BCRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.